Glioblastoma multiforme (GBM) (the deadliest form of brain cancer) is associated with poor survival rates (approximately 12-15 months from the time of diagnosis). This is due to the fact that most cases of GBM are resistant to current standards of care. As a result, novel effective treatment options are highly desirable. It has recently been […]
Read More